Yeo lab:Projects: Difference between revisions
No edit summary |
No edit summary |
||
| Line 10: | Line 10: | ||
*[[Yeo_lab:pulmonary | Pulmonary drug delivery for local therapy]]. | *[[Yeo_lab:pulmonary | Pulmonary drug delivery for local therapy]]. | ||
*[[Yeo_lab:solvent_exchange | Developing growth factor delivery systems for tissue engineering applications]]. | *[[Yeo_lab:solvent_exchange | Developing growth factor delivery systems for tissue engineering applications]]. | ||
|}<br style="clear:both" /> | |}{{Yeo_end_tool}}<br style="clear:both" /> | ||
Revision as of 15:28, 25 June 2008
|
One of the major obstacles in translating potent drug candidates from bench to bedside is their spatiotemporally adequate delivery. For example, small interfering RNA (siRNA) or peptide nucleic acid (PNA) have been recognized as a promising new class of drugs for viral infections, neurodegenerative diseases, and cancer; however, its therapeutic potential has not been realized because of inefficient delivery to the target cells. Target-specific delivery of anti-cancer drugs with minimal side effects on normal tissues has long been a goal for cancer therapy, but their clinical application remains challenging. Dr. Yeo’s lab will focus on developing drug/gene delivery systems which can address these challenges in delivery. Specific research projects include: |
